Equities

Oncimmune Holdings PLC

ONC:LSE

Oncimmune Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)23.00
  • Today's Change-1.10 / -4.56%
  • Shares traded37.64k
  • 1 Year change-43.07%
  • Beta0.7119
Data delayed at least 20 minutes, as of May 03 2024 14:12 BST.
More ▼

Profile data is unavailable for this security.

About the company

Oncimmune Holdings plc is a United Kingdom-based immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiaries include Oncimmune Americas LLC, Oncimmune Germany GmbH, and Oncimmune LLC, among others.

  • Revenue in GBP (TTM)1.15m
  • Net income in GBP-6.15m
  • Incorporated2015
  • Employees56.00
  • Location
    Oncimmune Holdings PLC1 Park RowLEEDS LS1 5ABUnited KingdomGBR
  • Phone+44 11 5823 1869Fax+44 11 5823 1958
  • Websitehttps://www.oncimmune.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Chill Brands Group PLC146.62k-3.64m11.14m2.0011.14m2.00
Kanabo Group PLC813.00k-4.66m11.70m20.0011.70m20.00
Abingdon Health PLC5.34m-2.24m11.87m82.0011.87m82.00
Synairgen plc0.00-9.99m12.32m30.0012.32m30.00
Shield Therapeutics PLC7.21m-46.89m12.90m28.0012.90m28.00
Incanthera PLC0.00-1.48m12.91m8.0012.91m8.00
Genincode PLC1.72m-6.73m13.05m28.0013.05m28.00
Provexis plc598.08k-496.59k14.71m2.0014.71m2.00
LungLife AI Inc36.71k-4.32m17.31m15.0017.31m15.00
Destiny Pharma PLC0.00-5.66m17.39m20.0017.39m20.00
Verici DX PLC15.16k-8.95m17.58m14.0017.58m14.00
OptiBiotix Health PLC689.10k-13.17m17.63m3.0017.63m3.00
Oncimmune Holdings PLC1.15m-6.15m17.87m56.0017.87m56.00
Skinbiotherapeutics PLC161.65k-2.88m18.54m11.0018.54m11.00
Hemogenyx Pharmaceuticals PLC0.00-6.69m21.03m17.0021.03m17.00
Oxford Biodynamics PLC510.00k-10.83m25.26m45.0025.26m45.00
Data as of May 03 2024. Currency figures normalised to Oncimmune Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

9.86%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 31 Aug 20233.14m4.23%
Chelverton Asset Management Ltd.as of 31 Aug 20233.01m4.06%
Unicorn Asset Management Ltd.as of 31 Mar 20241.16m1.57%
Gabelli Funds LLCas of 29 Dec 20232.90k0.00%
More ▼
Data from 30 Sep 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.